Anixa Biosciences (ANIX) Total Current Liabilities (2010 - 2026)

Anixa Biosciences (ANIX) has reported Total Current Liabilities for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 20.46% year-over-year to $1.5 million; the trailing twelve-month figure through Apr 2026 stood at $1.5 million (down 20.46% YoY), and the FY2025 full-year result was $2.0 million, down 21.32% from the prior year.
• Total Current Liabilities retreated to $1.5 million in Q2 2026 per ANIX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $2.5 million in Q4 2024 and bottomed at $1.2 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $1.8 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 60.39% in 2022, then plunged 31.06% in 2023.
• Over 5 years, Total Current Liabilities stood at $2.0 million in 2022, then declined by 0.44% to $2.0 million in 2023, then grew by 23.27% to $2.5 million in 2024, then declined by 21.32% to $2.0 million in 2025, then decreased by 23.69% to $1.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.5 million, $2.0 million, and $2.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.